METiS Therapeutics Inc.

Disappointing news appeared to overflow in the South Korean biotech sector in the second quarter amid multiple returned assets from global partners, a lack of major new out-licensing deals, as well as

Large funding rounds backed by both venture capital (VC) and private equity (PE) firms have recently reappeared in the China biotech space, suggested a recovery in the financing environment. Hangzhou-

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Astellas Taps Selecta For Gene The